Peptide Modifications For PEGylation

WATERTOWN, Mass. - Aug. 18, 2020 - PRLog -- PEGylation is the process of covalently attaching polyethylene glycol (PEG) polymer chains to peptides. By increasing their molecular mass and shielding them from proteolytic enzymes, PEGylation improves the pharmacokinetics of peptides and proteins. PEGylation reduces renal clearance and results in more sustained absorption after subcutaneous administration, as well as restricted distribution. PEGylations have been shown to significantly improve water solubility, biocompatibility, immunogenicity, and other physico-chemical properties. It is an established method for the delivery of biopharmaceuticals.

The Glutathione (GSH), a tripeptide formed from glutamic acid, cysteine and glycine, is active in many biological redox reactions. The conjugation of glutathione to its PEGylated liposome can be transported through the blood brain barrier in vivo via a sodium-dependent transporter. The GSH PEGylated liposomes enhance delivery of a fluorescent marker in the brain.

Biochempeg will PEGylate your peptide, or small molecule, and deliver your PEGylated product with a certificate of analysis, as a regular end-product, for further testing at your site. As a global partner, we can supply commercial quantities of high quality functionalized PEGs, which are essential for your PEGylated therapeutic proteins.

Our PEGylation services include:

①Multiple choices: amine reactive PEG acid, carbonyl reactive aminooxy PEG, click chemistry alkyne PEG and PEG azide, DBCO PEG, lipid PEG in drug delivery DSPE PEG, thiol reactive PEG Maleimide

②PEGylation feasibility studies

③Pilot production and process development of PEG-drug conjugate

④Development of PEGylated biosimilars

Pharmacological advantages of peptide PEGylation:

Improved peptide solubility and enhanced protection from proteolytic degradation. The PEG polymer, along with its associated water molecules, acts like a shield to protect the attached peptide drug from enzyme degradation, thereby limiting adverse immunological effects. PEGylated peptides are more stable over a range of pH and temperature changes compared with their un-PEGylated counterparts.

②Reduced dosing frequency with potentially reduced toxicity. PEG exhibits little toxicity, and is eliminated intact from the body by either the kidneys (for PEGylated drugs <30 kDa) or in the feces (for PEGylated drugs >20 kDa).

③Increased peptide or drug stability and extended circulating life. PEG lacks immunogenicity, and antibodies against PEG in rabbits are generated only if it is combined with highly immunogenic proteins.

Biochempeg is dedicated to manufacturing and supplying high purity polyethylene glycol (PEG) derivatives and linkers, monodisperse PEG, ADC PEG linkers, Click Chemistry reagents, PEGylation services and custom PEG derivative synthesis to clients worldwide. These PEG linkers have been widely used in bioconjugation, antibody-drug conjugates (ADCs) therapeutic, drug delivery and diagnostics field.

Official Website: https://www.biochempeg.com/